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The importance of resting heart rate (HR) as a prognostic factor and potential therapeutic target is not yet gen-
erally accepted. Recent large epidemiologic studies have confirmed earlier studies that showed resting HR to be
an independent predictor of cardiovascular and all-cause mortality in men and women with and without diag-
nosed cardiovascular disease. Clinical trial data suggest that HR reduction itself is an important mechanism of
benefit of beta-blockers and other heart-rate lowering drugs used after acute myocardial infarction, in chronic
heart failure, and in stable angina pectoris. Pathophysiological studies indicate that a relatively high HR has di-
rect detrimental effects on the progression of coronary atherosclerosis, on the occurrence of myocardial isch-
emia and ventricular arrhythmias, and on left ventricular function. Studies have found a continuous increase in
risk with HR above 60 beats/min. Although it may be difficult to define an optimal HR for a given individual, it
seems desirable to maintain resting HR substantially below the traditionally defined tachycardia threshold of 90
or 100 beats/min. These findings suggest that the potential role of HR and its modulation should be considered
in future cardiovascular guidance documents. (J Am Coll Cardiol 2007;50:823–30) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.079c
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teart rate (HR) is a familiar and accessible clinical variable.
ased on epidemiologic data and inferences from clinical
rials designed for other purposes, most physicians believe
hat tachycardia at rest is prognostically undesirable. How-
ver, the importance of HR as a prognostic factor and
otential therapeutic target has not been formally explored,
nd therefore, despite suggestive evidence, is not generally
ccepted. The aim of this article is to review the data
ssociating resting HR and mortality, the possible patho-
hysiological basis of this association, and the likelihood of
herapeutic utility of HR slowing in improving cardiovas-
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007, accepted April 10, 2007.ular outcomes for a wide range of patients. The profile of
hange in HR during and after exercise is also important
rognostically (1), but will not be considered here.
pidemiologic Data Associating HR and Outcome
significant association between resting HR and all-cause and
ardiovascular mortality has been reported in numerous epide-
iologic studies over the last 25 years (see reviews by Palatini
t al. [2,3]), and pertains in both the general population and in
hose with various cardiovascular diseases, including hyperten-
ion, acute myocardial infarction (AMI), and heart failure or
eft ventricular dysfunction. For example, in a recent study of
0,267 patients with acute coronary syndromes, mortality at 30
ays and 10 months increased progressively and significantly
ith HR (4). Moreover, in many studies, multivariate analysis
as shown HR to be an independent predictor of mortality
fter correction for demographic and clinical variables (includ-
ng blood pressure).
Two recent large studies with particularly lengthy
ollow-up have extended our understanding of the prognos-
ic importance of HR. In the first of these (1), resting and
xercise HR were measured in 5,713 working men, age 42
o 53 years and without known or suspected cardiovascular
isease, who then were followed up for a mean of 23 years.
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Resting Heart Rate in Cardiovascular Disease August 28, 2007:823–30All-cause mortality and sudden
and nonsudden death from AMI
each increased progressively with
resting HR, and remained signif-
icant after adjustment for exer-
cise capacity (evaluated by bicycle
ergometry), age, diabetes, sys-
olic arterial pressure, body mass index, level of physical
ctivity, and other factors. The relationship was steepest for
udden death (Fig. 1).
The second study (5) involved 24,913 men and women
ith suspected or proven coronary artery disease who had
een entered into the Coronary Artery Surgery Study
egistry. Median follow-up was 14.7 years. Both all-cause
nd cardiovascular mortality were directly related to resting
R at study entry. This predictive capacity was independent
f concomitant hypertension, diabetes, and smoking, and
lso of left ventricular ejection fraction and number of
iseased coronary vessels. Hazard ratios were similar for
ll-cause and cardiovascular mortality (Fig. 2), and among
en and women, old (65 years) and young patients,
ypertensive and normotensive patients, diabetic and non-
iabetic patients, those with left ventricular ejection
raction 50% and 50%, and those with a body mass
ndex 27 and 27 kg/m2.
In evaluating published data relating HR and outcome,
he impact of gender requires comment. Although average
ife span is modestly longer in women than in men, it is well
ocumented that, when adjusted for age, HR in women
verages 2 to 7 beats/min higher than in men (6,7). Clearly,
any factors in addition to HR influence survival duration;
he effects of some of these factors certainly must differ in
en and women. Nonetheless, within each gender, the
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Figure 1 Heart Rate and Mortality in Healthy Men
Relative risk of death from any cause, nonsudden death from myocardial infarc-
tion (MI), and sudden death from MI by quintiles of resting heart rate in 5,713
men without known or suspected heart disease. Reprinted with permission
from Jouven et al. (1). bpm  beats/min.(elationship of HR and both all-cause and cardiovascular
ortality rates is qualitatively similar (6).
Resting HR currently is included in risk assessment
ndices for patients after acute coronary syndromes (e.g., the
lobal Registry of Acute Coronary Events risk prediction
core [8]) and AMI (e.g., the Gruppo Itialiano per lo Studio
ella Sopravvivenza nell’Infarto Miocardico Prevenzione
isk assessment model [9] and the Thrombolysis in Myo-
ardial Infarction Risk Score [10]). Indeed, a model of only
variables (HR, age, and systolic arterial pressure) (11) has
een validated in a large, unselected group of patients with
T-segment elevation AMI (12).
Nonetheless, HR is not included in some widely
nown indices for cardiovascular risk (Copenhagen Risk
core [13], European SCORE project [14]), but has been
ncluded in the recent Cooper Clinic risk index for overall
ortality (15). In the latter study, involving 21,766 men,
stepwise proportional hazards model showed relatively
igh HR to be an independent predictor of all-cause
ortality, even though cardiorespiratory fitness was also
ncluded in the model. Heart rate was assigned the same
eighting as blood pressure and cardiorespiratory fitness
n the overall score (15).
harmacological HR Reduction: Possible Benefits
t least 2 drug groups widely used in cardiovascular disease,
eta-blockers and nondihydropyridine calcium channel
lockers, have an HR-lowering action. Effects on mortality
mong some patient groups are evident with beta-blockers
Figure 2 Heart Rate and Mortality in Coronary Artery Disease
Relationship between hazard ratio and resting heart rate for all-cause and car-
diovascular mortality in 24,913 patients with suspected or proven coronary
artery disease. Based on data from Diaz et al. (5). bpm  beats/min.patients with AMI or heart failure) and seem to be
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August 28, 2007:823–30 Resting Heart Rate in Cardiovascular Diseasessociated, at least in part, with the drug-mediated HR
eduction. Also, HR lowering has long been associated with
revention of exercise-induced angina and ischemia. Con-
umption of omega 3 fatty acids, found in fatty fish and fish
il, is associated with a modest (1 to 2 beats/min) reduction
n HR, but a recent systematic review concluded that
ong-chain and shorter-chain omega 3 fats do not have a
lear effect on total mortality, combined cardiovascular
vents, or cancer (16).
ortality in patients with coronary artery disease/
MI. There is good evidence showing that the beneficial
ffects of beta-blockers after AMI are related to reduction in
R. Kjekshus (17) reviewed early randomized trials in
hich beta-blockers were given within 6 h of the onset of
ymptoms. For 6 trials for which estimates of infarct size
nd HR were available, involving 1,427 patients, the mean
eduction in infarct size, relative to placebo, was directly
elated to the mean reduction in HR (p  0.001).
Kjekshus (17) also reviewed long-term trials of beta-
lockers after AMI. In 11 placebo-controlled trials involv-
ng more than 16,000 patients, a significant association was
ound between the reduction in HR and reduction in
ortality (Fig. 3). The Norwegian Timolol Multicenter
tudy (18), published after the Kjekshus (17) analysis,
howed similar results. In this study, HR during follow-up
as a significant predictor of overall mortality. Timolol
reatment was associated with a 41.6% reduction in mortal-
ty, but mortality at a given HR was similar in the timolol
nd placebo groups. In logistic regression analysis, HR
emained predictive but treatment did not, indicating that
he major effect of timolol on mortality could be attributed
o its effect on HR. By contrast, the APSI (Acebutolol et
Figure 3 Heart Rate Reduction and
Mortality After Myocardial Infarction
Relationship between the mean reduction in heart rate and the mean change
in mortality (relative to placebo) in different randomized, placebo-controlled tri-
als of beta-blockers after myocardial infarction. The linear regression line (r 
0.6, p  0.05) was fitted excluding the smallest study (open circles). Modified
and based on data from Kjekshus (17). bpm  beats/min.brévention Secondaire de l’Infarctus) study in high-risk
atients with AMI suggested that low-dose treatment with
cebutolol produced large reductions in all-cause and car-
iovascular mortality (of 48% and 58%, respectively) in spite
f only a modest effect on HR (19).
xercise-induced angina and ischemia. When HR-
owering drugs have been used, angina reduction is related
o HR reduction in patients with chronic coronary artery
isease (20,21). Reduction in underlying ischemia also can
e attributed to HR reduction. In a double-blind study
omparing low and high doses of 3 different calcium
hannel blockers in 335 stable angina patients, the improve-
ents in time to ischemia during bicycle exercise tolerance
ests were directly related to the reductions in exercise HR
Fig. 4). Regression analysis showed that the beneficial
nti-ischemic effect of the drugs was largely dependent on
heir effect on HR (22).
ortality in patients with heart failure. Kjekshus and
ullestad (23) analyzed the relation of treatment to HR and
utcome in patients with heart failure. Here, as for AMI, a
elationship was found between reduction in HR and in
ortality; in addition, agents that increased HR tended to
ncrease mortality (Fig. 5).
Results of most recent studies in heart failure have been
onsistent with this finding. For example, in the CIBIS
Cardiac Insufficiency Bisoprolol Study) trial, treatment
ith bisoprolol reduced HR by approximately 15 beats/min
elative to placebo; HR reduction was the most powerful
redictor of survival in multivariate analysis (24). The
elationship between log hazard for mortality and HR
hange was almost linear over the range 40 to 10
R2 = 0.962
0
10
20
30
40
50
60
70
0 5 10 15 20 25
Heart rate reduction (bpm)
C
ha
ng
e 
in
 ti
m
e 
to
 m
yo
ca
rd
ia
l
is
ch
em
ia
 (
s)
Figure 4 Heart Rate Reduction and Myocardial Ischemia
Relationship between the improvement in time to myocardial ischemia during
bicycle exercise and the reduction in exercise heart rate achieved in stable
angina patients after treatment with 2 doses of 3 different calcium channel
blockers (amlodipine, diltiazem, and mibefradil). Reprinted with permission
from van der Vring et al. (22). bpm  beats/min.eats/min. In the larger CIBIS II trial (25), baseline HR
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Resting Heart Rate in Cardiovascular Disease August 28, 2007:823–30nd HR change both were significant predictors of mortal-
ty. The best prognosis was obtained in patients with the
owest baseline HR and with the greatest HR reduction,
nd as expected, these conditions were met more frequently
n the bisoprolol group than in the placebo group.
In an analysis of data from the COMET (Carvedilol or
etoprolol European Trial) study, HR achieved during
eta-blocker therapy was a significant independent predic-
or of mortality, although HR did not influence the greater
urvival benefit with carvedilol compared with metoprolol
26). In the MERIT-HF (Metoprolol CR/XL Randomized
ntervention Trial in Congestive Heart Failure) study,
owever, the benefits with metoprolol were independent of
he change in HR achieved (27), suggesting that HR
eduction is not the only mechanism of benefit of beta-
lockers in heart failure.
athophysiological Mechanisms
therosclerosis and Arterial Stiffness
n cynomolgus monkeys, naturally occurring differences in
R are related to the extent of coronary artery atheroscle-
osis (28); HR reduction by sinoatrial node ablation reduces
oth severity of individual atherosclerotic stenoses and the
rea covered by lesions within the coronary arteries (29). In
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Figure 5 Heart Rate Reduction and Mortality in Heart Failure
Relationship between mean change in heart rate and mean change in mortality
in studies of patients with chronic heart failure. Reprinted with permission from
Kjekshus and Gullestad (23). ANZ  Australia/New Zealand Heart Failure
Research Collaborative Group; BHAT  Beta Blocker Heart Attack Trial; bpm 
beats/min; CIBIS  Cardiac Insufficiency Bisoprolol Study; CONSENSUS 
Cooperative North Scandinavian Enalapril Survival Study; GEISCA  Grupo de
Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina; HDZ/ISDN 
hydralazine/isosorbide dinitrate; MOCHA  Multicenter Oral Carvedilol Heart
Failure Assessment; NOR TIMOLOL  Norwegian Multicentre Study Group;
PROFILE  Prospective Randomized Flosequinan Longevity Evaluation; PROM-
ISE  Protection Devices in PCI-Treatment of Myocardial Infarction for Salvage
of Endangered Myocardium Study; SOLVD  Studies of Left Ventricular Dys-
function; US CARVEDILOL  U.S. Carvedilol Heart Failure Study Group; VHeFT
 Vasodilator in Heart Failure Trials; XAMOTEROL  Xamoterol in Severe Heart
Failure Study Group.umans, HR is directly associated with progression of toronary atherosclerosis (30), and also has been significantly
elated to the likelihood of disruption of pre-existing ath-
rosclerotic plaque (31).
Increases in HR induced by electrical pacing in rats are
ccompanied by progressive and marked reductions in
rterial compliance and distensibility (32). Similarly, HR is
trongly and directly associated with arterial rigidity in
ypertensive patients, after adjustment for age and blood
ressure (33).
These results suggest that HR impacts directly on the
tatus of the arterial wall, probably because of mechanical
ulsatile stress, and also possibly involving the proinflam-
atory actions of oscillatory fluid shear stresses acting on
he vascular endothelium (34).
yocardial Ischemia
he basis of myocardial ischemia is disordered balance
etween myocardial oxygen demand and supply. Heart rate
mportantly influences both factors, as the primary determi-
ant of myocardial oxygen demand and as controller of
upply. Experimental studies have shown that increasing
R increases oxygen demand even when the external work
erformed by the heart is kept constant, partly because of a
reater oxygen requirement for excitation-contraction cou-
ling (35).
Myocardial perfusion occurs predominantly during dias-
ole, and the fraction of the cardiac cycle occupied by
iastole increases as HR decreases. Therefore, HR reduc-
ion improves diastolic perfusion time. Furthermore, in-
reasing HR by atrial pacing in patients with coronary artery
isease produces coronary vasoconstriction, potentially fur-
her impairing oxygen supply (36).
In patients with stable coronary artery disease, most
pisodes of ambulatory or exercise-induced myocardial isch-
mia are preceded by an increase in HR (37). The likelihood
f developing ischemia is related to the baseline HR and the
agnitude and duration of the increase (38). The frequency
f ambulatory ischemic episodes in treated patients with
oronary artery disease is related to their mean HR: patients
ith HR 80 beats/min experience ischemia almost twice
s often as those with HR 70 beats/min (39).
In dogs with experimental coronary stenosis, exercise-
nduced regional contractile dysfunction is reduced by beta-
lockade, but the improvement is prevented if HR is kept at
re–beta-blockade levels by atrial pacing (40). Similarly, in
atients with angina pectoris, beta-blockade does not reduce
yocardial oxygen demand or ischemia if angina is induced
y atrial pacing (41).
entricular Arrhythmias
n epidemiologic studies, HR is more strongly related to
udden death than to nonsudden death from AMI (1).
xperimental studies suggest that HR not only is important
n the development of ischemia, but also influences whether
schemic episodes trigger serious arrhythmias. Experimen-
ally, abrupt-onset myocardial ischemia is more likely to
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August 28, 2007:823–30 Resting Heart Rate in Cardiovascular Diseaseesult in ventricular tachycardia and fibrillation among dogs
ith a high spontaneous HR than in those with a lower HR
42,43). In open-chest pigs with experimental coronary
rtery occlusion, beta-blockade raises the threshold for
entricular fibrillation, an effect abolished if HR is kept
onstant by pacing (44). These experimental studies suggest
hat HR modulation can reduce the risk of life-threatening
rrhythmias during ischemic episodes; the beneficial effect
f beta-blockade in this context may be mediated primarily
y HR reduction.
Depressed HR variability is associated with the risk of
ife-threatening arrhythmias in patients after AMI (45).
here is some suggestion that HR variability assessed very
arly after AMI may not add prognostic information beyond
hat of HR alone (46). However, others have shown that
R variability is strongly predictive after AMI (47,48), even
hen assessed during the first 7 days (49).
ther Rhythm Disturbances
inus node disease. Severe sinus bradycardia may be a
eature of sinus node disease, and in turn related to
nderlying cardiovascular disease and ageing. In these cir-
umstances, any gain in cardiovascular survival related to the
ow HR would most likely be offset by the negative
onsequences and the causes of the sinus node disease.
trial fibrillation. In atrial fibrillation, HR is often patho-
ogically rapid. It may be controlled pharmacologically by
eta-blockade, calcium antagonists, and digitalis glycosides,
nd reduction of HR is generally assumed to be associated
ith improved survival. However, this has only been con-
incingly shown in atrial fibrillation patients in the post-
yocardial infarction or heart failure setting with some
eta-blockers such as carvedilol (50), but pharmacological
ctions other than HR reduction also may play a part (51).
n large rate versus rhythm control trials in patients with
trial fibrillation, HR reduction tended toward improved
urvival when compared with a rhythm control strategy (52).
owever, there is no evidence showing that strict HR
ontrol was superior to less stringent rate control (53). Atrial
brillation is a pathological cardiac arrhythmia, and the
ptimal degree of HR reduction in this situation is un-
nown.
eft Ventricular Dysfunction and Heart Failure
n dogs, left ventricular dysfunction caused by surgically
nduced mitral regurgitation is substantially ameliorated by
eta-blocker treatment, but the amelioration is largely
revented by electrical pacing to the pre–beta-blockade rate
54). In a rat model of heart failure, prolonged HR
eduction with an HR-lowering agent that has no direct
ction on myocardial contractility or the autonomic nervous
ystem improves left ventricular function and normalizes
tructure, including increasing capillary density (55). In
atients with heart failure, HR reduction by beta-blockade
educes oxygen requirement for nonmechanical work and
ncreases mechanical efficiency, benefits that are abolished if tR is kept constant by atrial pacing (56). In a recent study
57) in patients with heart failure fitted with permanent
acemakers and treated with beta-blockers, pacing at 80
eats/min as opposed to 60 beats/min attenuated or reversed
he beneficial effects of beta-blockade on left ventricular
olume and systolic function.
eart Rate: Independent Causative
actor or Merely an Epiphenomenon?
lthough the association of HR and outcome is suggestive,
t does not, by itself, prove causality. High HR also is
ssociated with poor cardiorespiratory fitness (58) or im-
aired cardiac function. Indeed, exercise capacity itself is a
owerful predictor of mortality (59), and resting HR is
ower in individuals who undertake vigorous leisure activi-
ies or participate in sports (60,61). Therefore, in recent
tudies significantly relating HR and mortality, adjustments
ave been made for the effects of physical activity and
ardiac function (1,5). In the Cooper Clinic Mortality Risk
ndex, high HR and low cardiorespiratory fitness were both
ndependent predictors of mortality (15).
Relatively high HR often is found together with other
ardiovascular risk factors, notably hypertension, an athero-
enic blood lipid profile, blood glucose and insulin levels,
nd overweight (62). Indeed, HR correlates with the num-
er of cardiovascular risk factors presenting in an individual
63). Nonetheless, in most recent epidemiologic studies,
hen adjustments are made for accepted risk factors, HR
till independently predicts risk.
The depolarization rate of the sinoatrial node is largely
etermined by the activity of the autonomic nervous system.
herefore, HR unquestionably is directly related to sympa-
hetic activity or autonomic imbalance. An important un-
esolved issue is the extent to which HR mediates the
eleterious effects of sympathetic hyperactivity. It is clear
hat the majority of the benefit of beta-1-adrenergic block-
de is mediated via HR reduction, but beta-blockers have
umerous other actions, some beneficial, some undesirable.
nderstanding the contribution of HR per se is likely to be
articularly useful in managing the large number of patients
ho might expect to benefit from HR reduction but who do
ot or cannot receive intensive beta-blocker therapy. Abso-
ute and relative contraindications, physician concerns, and
edication intolerance, among the major reasons for low
oses or nonprescription of beta-blocker therapy (64,65),
ay preclude optimal management for many patients.
In summary, it seems likely that relatively high HR is
oth causative and indicative of important pathophysiolog-
cal processes. Clarification of the utility of HR modulation
ay come from the use of specific HR-reducing drugs that
o not act via the autonomic nervous system. One such
gent has shown antianginal and anti-ischemic benefits in
atients with stable angina (66,67), but its effect on mor-
ality is not yet known.
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Resting Heart Rate in Cardiovascular Disease August 28, 2007:823–30s There an Optimal Heart Rate?
eart rate at rest varies widely, but a pattern of distribution
eems to exist. Thus, Palatini et al. (68) explored the shapes
f the frequency distributions of HR in 3 populations,
dentifying 2 subgroups, 1 larger, representing those with
normal” HR, and 1 smaller, with a “high” HR. The
egregation value between the subgroups varied between 75
nd 85 beats/min in the different populations. From the
pidemiologic data presented previously, it seems desirable
o maintain HR in the normal rather than in the high range,
nd specifically, to maintain resting HR substantially below
he traditionally defined tachycardia threshold of 90 or 100
eats/min.
Indeed, in recent large studies, there seems to be a
ontinuous increase in risk with HR, at least for values
bove approximately 60 beats/min, with no evidence of a
hreshold (1,5). However, data from the GUSTO-1 (Global
tilization of Streptokinase and TPA for Occluded Arter-
es) study suggest an increasing risk below 60 beats/min
69). Thus, it may be possible to define an HR at which
ardiovascular risk is optimized, although if it exists, such an
R may be expected to differ with underlying the physio-
ogical or pathophysiological state.
When considering a desirable or optimal HR for an
ndividual patient, demographic and measurement factors
lso must be taken into account. The HR has been reported
o decrease with age (3), although this has not been seen in
ll studies (7), and HR is higher in women than in men (7).
he HR shows a clear circadian rhythm, being substantially
igher during waking hours, but the variations are relatively
mall between 10 AM and 6 PM (70). Finally, HR also
hanges with posture, being some 3 beats/min higher in the
itting compared with the supine position (71). A recent
onsensus meeting recommended measurement of HR by
ulse palpation during two 30-s periods, performed in a
itting position, after 5 min sitting in a quiet room (72).
linic HR seems to carry as much prognostic information as
mbulatory measurements (6).
onclusions
urrent data leave little doubt that HR is a risk factor for
ardiovascular mortality, independent of currently accepted
isk factors and other potentially confounding demographic
nd physiological characteristics. However, until now it has
een difficult to determine whether modulation of HR can
eneficially alter risk; currently available interventions that
ower HR, such as beta-blockers, certain calcium channel
lockers, and physical conditioning have multiple additional
ctions. Nonetheless, the data we have presented suggest
hat improved understanding of the relationship between
R, its modification, and cardiovascular health is important
nd potentially beneficial for patient care. To realize this
enefit, awareness of the potential importance of HR must
e enhanced. Currently, HR is not recognized as a factor forardiovascular risk assessment or risk reduction in U.S. and
uropean guidelines (14,73,74). Emerging data presented
erein suggest that the potential role of HR and its
odulation should be seriously considered in future cardio-
ascular guidance documents.
eprint requests and correspondence: Dr. Kim Fox, Royal
rompton Hospital, Sydney Street, London SW3 6NP, England.
-mail: k.fox@rbh.nthames.nhs.uk.
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